Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

José María Roca,V. Alonso,C. Pericay,Pilar Escudero,Antonieta Salud,F. Losa,Luis-Jesús López,Imma Guasch,Miguel Méndez,Guillermo Quintero-Aldana,Carlos Grande,P. Vicente,A. Arriví,Cristina Martín,Isabel Moreno,Pilar Baca García,Isabel Antón,Manuel Constenla,A. Yubero,Luis Cirera

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

2010

Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 patients from 19 cent

Keywords:

Regimen
Cetuximab
Biology
Colorectal cancer
Metastasis
Irinotecan
General surgery
Oncology
Internal medicine
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations